Syros to Participate in Upcoming Investor Conferences

Contacts

Syros Contact


Karen Hunady


Director of Corporate Communications & Investor Relations


1-857-327-7321


khunady@syros.com

Investor Contact


Amanda Isacoff


Stern Investor Relations, Inc.


212-362-1200


amanda.isacoff@sternir.com

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will participate in a fireside chat at two upcoming investor conferences. Details are as follows:

JMP Securities 2024 Life Sciences Conference


Date: Tuesday, May 14


Presentation Time: 11:00 a.m. ET


Location: New York Hilton Midtown, 1335 Sixth Avenue, New York, NY

TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA


Date: Wednesday, May 29


Presentation Time: 1:00 p.m. ET


Location: Virtual

To access the webcasts and subsequent archived recording of each event, please visit the Investors & Media section of the Syros website at www.syros.com. An archived replay of each webcast will be available for approximately 30 days following each presentation.

About Syros Pharmaceuticals

Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.